Palonosetron versus other 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States

Journal of Medical Economics

Volumn 14, Issue 3, 2011, Pages 341-349

  Craver, Chris ^a   Gayle, Julie ^a   Balu, Sanjeev ^b   Buchner, Deborah ^b  

^a Premier Inc   (United States)

^b EISAI INC   (United States)

Author keywords

Antiemetic therapy; Cancer emesis; Chemotherapy; Hematologic malignancies; Hospital outpatient setting; Nausea; Vomiting

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BUTYROPHENONE; CANNABINOID DERIVATIVE; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE DERIVATIVE; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEHYDRATION; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOVOLEMIA; INCIDENCE; LEUKEMIA; LINEAR REGRESSION ANALYSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTPATIENT CARE; PROPHYLAXIS; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; OUTPATIENTS; QUINUCLIDINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; UNITED STATES; VOMITING; YOUNG ADULT;

EID: 79956108294     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.582908     Document Type: Article

References (37)

1. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007;15:497-503 (Pubitemid 46570778)
2. Morrow GR, Roscoe JA, Hickok JT, et al. Initial control of chemotherapyinduced nausea and vomiting in patient quality of life. Oncology 1998;12(Suppl 4):32-7
3. Sussman N. Reactions of patients to the diagnosis and treatment of cancer. Anticancer Drugs 1995;6(Suppl 1):4-8
4. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-6 (Pubitemid 29297482)
5. Grunberg SM, Osoba D, Hesketh PJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-4 (Pubitemid 40558162)
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in OncologyTM: Antiemesis. Version 2.2010. Available at: http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp [Accessed March 1, 2011]
7. Einhorn LH, Rapoport B, Koeller J, et al. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-16 (Pubitemid 40558167)
8. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther 2010;10:137-48
9. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapyinduced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8 (Pubitemid 38580348)
10. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 2003;98:2473-82 (Pubitemid 37466663)
11. Aapro MS, Grunberg GM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Annal Oncol 2006;17:1441-9 (Pubitemid 44400384)
12. Rzepecki P, Pielichowski W, Oborska S, et al. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation - single center experience. Transplant Proc 2009;41:3247-3249 doi:10.1016/j.transproceed.2009.07.071
13. Mattiuzzi GN, Cortes JE, Blamble DA, et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010;116:5659-66
14. Musso M, Scalone R, Bonanno V, et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009;17:205-9
15. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64:1125-32 (Pubitemid 38736896)
16. Aloxi injection (palonosetron hydrochloride) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc, 2009
17. López-Jiménez J, Martín-Ballesteros E, Sureda A, et al. Chemotherapyinduced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006;91:84-91 (Pubitemid 43235390)
18. Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association (AMIA) 2003 Symposium Proceedings: 1050
19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83 (Pubitemid 17055592)
20. Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95 (Pubitemid 36056305)
21. Tremblay P, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21:2147-55 (Pubitemid 46606363)
22. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxtryptamine type 3 receptor antagonist according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20:2805-11 (Pubitemid 34651509)
23. Abali H, Celik I. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Cancer Invest 2007;25:135-9 (Pubitemid 47164856)
24. Walsh T, Morris AK, Holle LM, et al. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant 2004;34:963-8 (Pubitemid 39600113)
25. Tan M, Xu R, Seth R. Granisetron vs dolasetron for acute chemotherapyinduced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study. Curr Med Res Opin 2004;20:879-82 (Pubitemid 38821526)
26. Fox-Geiman MP, Fisher SG, Kiley K, et al. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant 2001;7:596-603 (Pubitemid 33130592)
27. Slaby J, Trneny M, Prochazka B, et al. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. Neoplasma 2000;47:319-22
28. Spitzer TR, Friedman CJ, Bushnell W. Double-blind randomized parallel-group study on the efficacy safety of oral granisetron oral ondansetron in the prophylaxis of nausea vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Trans 2000;26:203-10 (Pubitemid 30496968)
29. Orchard PJ, Rogoscheske J, Burns L, et al. A prospective randomized trial of the anti-emetic efficacy of ondansetron and granisetron during bone marrow transplantation. Biol Blood Marrow Transplant 1999;5:386-93
30. Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving moderately or highly emetogenic chemotherapy (MEC/HEC). Presented at the 2010 ISPOR European Congress, November 6-9, 2010; Prague, Czech Republic
31. Schwartzberg L, Szabo S, Gilmore J, et al. Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderate or highly emetogenic chemotherapy (LEC/MEC/HEC). Curr Med Res Opin 2011;27:837-45 doi: 10.1185/03007995.2011.556603
32. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9 doi:10.1016/j.ejphar.2009.10.002
33. American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society, 2010
34. Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008;16:201-8
35. Osoba D, Zee B, Pater J, et al. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-23
36. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States. Blood 2006;107:265-276 doi: 10.1182/blood-2005-06- 2508 (Pubitemid 43053551)
37. Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev 2003;22:87-93 (Pubitemid 36363517)